<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">

  <link rel="icon" type="image/x-icon" href="favicon.ico"/>
  <link rel="shortcut icon" href="favicon.ico" />
  <link rel="icon" sizes="16x16" href="assets/favicon-16x16.png" />
  <link rel="icon" sizes="32x32" href="assets/favicon-32x32.png" />
  <link rel="icon" sizes="192x192" href="assets/android-chrome-192x192.png" />
  <link rel="apple-touch-icon" sizes="180x180" href="assets/apple-touch-icon.png" />

  <!-- <meta name="description" content="" /> -->
  <meta property="og:site_name" content="Epikast" />
  <meta property="og:title" content="About" />
  <!-- <meta property="og:description" content="Page description" /> -->
  <meta name="keywords" content="patients, prescribers, caregivers, data, insights">
  <meta property="og:image" content="assess/og_img.png" />

  <link rel="stylesheet" href="css/layout/layout.css">
  <link rel="stylesheet" href="css/pages/about.css">

  <title>About us</title>
</head>
<body>

  <header>
    <div class="container container--header">
      <a href="index.html" class="logo">
        <figure>
          <img src="assets/logo.svg" alt="Epikast logo" width="158" height="36">
        </figure>
      </a>
      <nav class="menu-wrap js-menu">
        <ul class="menu">
          <li><a href="services.html">Our services</a></li>
          <li><a href="about.html" class="active">About us</a></li>
          <li><a href="careers.html">Careers</a></li>
          <li><a href="contact.html">Contact us</a></li>
        </ul>
      </nav>
      <span class="burger js-burger"></span>
    </div>
  </header>

  <main class="container container--main">
    
    <section class="quotes">
      <article class="split split--double quote">
        <div class="split__part quote__content">
          We redefine how biopharmaceutical companies engage with 
          their most important stakeholders:
          <strong>patients / caregivers and prescribers.</strong>
        </div>
        <figure class="split__part rounded layered">
          <img src="assets/images/about_1.jpg" width="576" height="400" />
        </figure>
      </article>
      <article class="split split--double quote">
        <figure class="split__part rounded layered">
          <img src="assets/images/about_2.jpg" width="576" height="400" />
        </figure>
        <div class="split__part quote__content">
          We focus on collecting and synthesizing all appropriate 
          <strong>data</strong> from those interactions, enabling our partners to 
          gain <strong>unique insights</strong> into the use of their medications 
          in the real world.
        </div>
      </article>
    </section>

    <section class="values bubble">
      <h2 class="bubble__title">Our values</h2>
      <div class="values__wrap js-values">
        <ul class="split split--double values__list">
          <li class="split__part values__item">
            <h3 class="value__title">
              <img src="assets/Care.svg" width="40" height="40" alt="Care" /> Care
            </h3>
            <div class="content">
              We care deeply for the patients we serve. 
              Everything we do is aimed towards improving their lives.
              Equally, we deeply care about our customers and about each other. 
              We value our relationships and we help each other grow as professionals
            </div>
          </li>
          <li class="split__part values__item">
            <h3 class="value__title">
              <img src="assets/Excellence.svg" width="40" height="40" alt="Excellence" /> Excellence
            </h3>
            <div class="content">
              Simply put, we never compromise. We strive for excellence 
              in everything we do, and we continuously learn from our 
              customers and from each other.
            </div>
          </li>
          <li class="split__part values__item">
            <h3 class="value__title">
              <img src="assets/Innovation.svg" width="40" height="40" alt="Innovation" /> Innovation
            </h3>
            <div class="content">
              We don’t ask how things have been done in the past, 
              but how they should be done in 10 years from now. 
              We live and breathe technology and data,
              while maintaining our core of a human-centric business.
            </div>
          </li>
          <li class="split__part values__item">
            <h3 class="value__title">
              <img src="assets/Integrity.svg" width="40" height="40" alt="Integrity" /> Integrity
            </h3>
            <div class="content">
              We do not overpromise to our customers, we do not bend 
              any rules ever, and we treat our stakeholders – patients, 
              physicians, customers, employees, and our communities – 
              exactly how we would want to be treated.
            </div>
          </li>
        </ul>
        <div class="pagination pagination--values"></div>
      </div>
      <img src="assets/element_3.svg" class="values__element">
    </section>

    <section class="personas">
      <h2 class="personas__title">Our leadership</h2>
      <div class="personas__wrap js-personas">
        <div class="split split--quadraple">
          <article class="split__part persona">
            <div class="persona__card">
              <figure class="persona__image">
                <img src="assets/images/Vangelis_vergetis.jpg" width="152" height="160" alt="Vangelis Vergetis" />
              </figure>
              <h3 class="persona__title">Vangelis Vergetis, PhD</h3>
              <div class="persona__desc">CEO and board member</div>
              <img class="persona__arrow" src="assets/arrow.svg">
            </div>
            <div class="persona__bio-wrap">
              <div class="persona__bio">
                <img class="persona__close" src="assets/close.svg" alt="">
                <div class="persona__content content">
                  <p>
                    Vangelis has been working in the intersection 
                    of healthcare, technology, and data science 
                    for more than 15 years.
                  </p>
                  <p>
                    He initialy worked as a consultant at McKinsey and at Hakluyt 
                    for about a douzen years, advising biopharmaceutical executives 
                    on several topics - particularly in launching drugs across 
                    disease areas, and in designing and putting in 
                    place their commercial models and infrastructure. 
                  </p>
                  <p>
                    
                  </p>
                  <p>
                    Immediately prior to Epikast, Vangelis was the 
                    co-founder and CEO of Intelligencia, a software 
                    company that utilizes AI to assess and reduce 
                    the risk of clinical trials. He currently serves 
                    as a board advisor to the company.
                  </p>
                  <p>
                    He is a board member and member of the executive committee 
                    at the Alliance for AI in Healthcare (AAIH), 
                    and a former member of the advisory board for 
                    Cornell's Bowers College of Computing &amp; 
                    Information Science (CIS).
                  </p>
                  <p>
                    Vangelis holds a 
                    PhD in Electrical Engineering from the University 
                    of Pennsylvania, and a BS in 
                    Computer Science from Cornell.
                  </p>
                </div>
                <span class="persona__shadow"></span>
                <a href="https://www.linkedin.com/in/vangelisvergetis" target="_blank" class="linkedin">
                  <svg id="Layer_1" data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 40">
                    <g id="Group_330" data-name="Group 330" fill="#fff">
                      <path id="Path_177" data-name="Path 177" class="cls-1" d="m13.27,31.23h-5.06V15.17h4.97v16.06h.09Zm-2.53-18.21c-1.6-.09-2.82-1.46-2.73-3.06.08-1.47,1.26-2.65,2.73-2.73,1.6.09,2.82,1.46,2.73,3.06-.08,1.47-1.26,2.65-2.73,2.73Zm21.25,18.21h-4.96v-7.83c0-1.87,0-4.3-2.62-4.3s-2.99,2.09-2.99,4.11v7.94h-5.05v-15.99h4.78v2.15h.1c.98-1.69,2.81-2.7,4.77-2.62,5.06,0,6,3.36,6,7.66v8.87h-.01Z"/>
                    </g>
                  </svg>
                </a>
              </div>
            </div>
          </article>
          <article class="split__part persona">
            <div class="persona__card">
              <figure class="persona__image">
                <img src="assets/images/Stelios_papadopoulos.jpg" width="152" height="160" alt="Stelios Papadopoulos" />
              </figure>
              <h3 class="persona__title">Stelios Papadopoulos, PhD</h3>
              <div class="persona__desc">Chairman of the board</div>
              <img class="persona__arrow" src="assets/arrow.svg" alt="">
            </div>
            <div class="persona__bio-wrap">
              <div class="persona__bio">
                <img class="persona__close" src="assets/close.svg" alt="">
                <div class="persona__content content">
                  <p>
                    Stelios brings more than four decades of experience in the 
                    biopharmaceutical industry in various roles: as a company founder, 
                    executive, investment banker, and leader in the global healthcare 
                    sector.
                  </p>
                  <p>
                    Stelios is Chairman of the Board of Directors of Biogen, Inc., 
                    Exelixis, Inc., and Regulus Therapeutics, Inc. He is a co-founder 
                    of Exelixis, as well as co-founder and former Chairman of Anadys 
                    Pharmaceuticals (acquired by Hoffman–La Roche in 2011) and 
                    Cellzome (acquired by GlaxoSmithKline in 2012). In 
                    the not-for-profit sector, Stelios is a member of the 
                    Board of Visitors of Duke Medicine, a member of the Global 
                    Advisory Board of the Duke Institute for Health Innovation, 
                    and co-founder and Chairman of Fondation Santé 
                    (<a href="www.fondationsante.org">www.fondationsante.org</a>), a foundation providing 
                    research support and mentorship to biomedical 
                    scientists in Greece and Cyprus.
                  </p>
                  <p>
                    Stelios spent six years (2000-06) at Cowen & Co., LLC, most 
                    recently as Vice Chairman, where as an investment banker he 
                    focused on the biotech and pharma sectors. Prior to joining 
                    Cowen, he spent 13 years as an investment banker at PaineWebber, 
                    Incorporated where he was most recently Chairman of 
                    PaineWebber Development Corp., a PaineWebber subsidiary 
                    focusing on biotechnology. He joined PaineWebber in 1987 
                    from Drexel Burnham Lambert where he was an analyst in 
                    the Equity Research Department covering the biotechnology industry. 
                    Prior to Drexel, he was the biotechnology analyst of Donaldson, 
                    Lufkin & Jenrette. Stelios has received multiple honors and 
                    awards for his work in the biopharma industry as a company 
                    founder, adviser, and financier.
                  </p>
                  <p>
                    Before coming to Wall Street, Stelios was on the faculty of the 
                    Department of Cell Biology at New York University School of 
                    Medicine. Stelios holds an M.S. in physics, a Ph.D. in biophysics 
                    and an M.B.A. in finance, all from New York University.
                  </p>
                </div>
                <span class="persona__shadow"></span>
              </div>
            </div>
          </article>
          <article class="split__part persona">
            <div class="persona__card">
              <figure class="persona__image">
                <img src="assets/images/Daphne.jpg" width="152" height="160" alt="Mike Krzan" />
              </figure>
              <h3 class="persona__title">Daphne Karydas</h3>
              <div class="persona__desc">Board member</div>
              <img class="persona__arrow" src="assets/arrow.svg" alt="">
            </div>
            <div class="persona__bio-wrap">
              <div class="persona__bio">
                <img class="persona__close" src="assets/close.svg" alt="">
                <div class="persona__content content">
                  <p>
                    Daphne has over 25 years of experience in 
                    financial and operations leadership roles 
                    focused in the biopharmaceutical industry, 
                    where she has brought an interdisciplinary 
                    approach to implementing growth strategies 
                    for biopharmaceutical and asset 
                    management companies.
                  </p>
                  <p>
                    She is currently the COO and CFO of Flare 
                    Therapeutics, which she joined in October 2021. 
                    Prior to Flare she was the CFO of Syndax 
                    Pharmaceuticals, and also served as SVP of 
                    Strategy and Corporate Financial Planning & 
                    Analysis at Allergan plc, where she oversaw 
                    the company’s long-term financial and 
                    business strategy until its acquisition 
                    by Abbvie in May 2020. She joined 
                    Allergan in April 2017 as the SVP of 
                    Global Investor Relations and Strategy, 
                    leading engagement with the investment 
                    community and business strategy development.
                  </p>
                  <p>
                    Prior to her senior operating roles in the industry, 
                    Daphne served as Executive Director and Senior 
                    Healthcare Analyst at J.P. Morgan Asset Management. 
                    Previously, she was a Portfolio Manager and Senior 
                    Healthcare Analyst at The Boston Company Asset 
                    Management, a BNY Mellon company. Earlier in 
                    her career she was a VP at Goldman Sachs Asset 
                    Management focused on healthcare, as well as a 
                    member of Goldman Sachs’ healthcare investment 
                    banking team. Before joining Goldman Sachs she 
                    was a Project Chemical Engineer at Merck, 
                    where she focused on process development 
                    for novel vaccines.
                  </p>
                  <p>
                    Daphne received a BA and MS in chemical engineering 
                    from MIT and an MBA from Harvard Business School.
                  </p>
                </div>
                <span class="persona__shadow"></span>
                <a href="https://www.linkedin.com/in/daphne-karydas-493b17/" target="_blank" class="linkedin">
                  <svg id="Layer_1" data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 40">
                    <g id="Group_330" data-name="Group 330" fill="#fff">
                      <path id="Path_177" data-name="Path 177" class="cls-1" d="m13.27,31.23h-5.06V15.17h4.97v16.06h.09Zm-2.53-18.21c-1.6-.09-2.82-1.46-2.73-3.06.08-1.47,1.26-2.65,2.73-2.73,1.6.09,2.82,1.46,2.73,3.06-.08,1.47-1.26,2.65-2.73,2.73Zm21.25,18.21h-4.96v-7.83c0-1.87,0-4.3-2.62-4.3s-2.99,2.09-2.99,4.11v7.94h-5.05v-15.99h4.78v2.15h.1c.98-1.69,2.81-2.7,4.77-2.62,5.06,0,6,3.36,6,7.66v8.87h-.01Z"/>
                    </g>
                  </svg>
                </a>
              </div>
            </div>
          </article>
          <article class="split__part persona">
            <div class="persona__card">
              <figure class="persona__image">
                <img src="assets/images/Dimitris_Papalexopoulos.jpg" width="152" height="160" alt="Dimitris Papalexopoulos" />
              </figure>
              <h3 class="persona__title">Dimitris Papalexopoulos</h3>
              <div class="persona__desc">Board member</div>
              <img class="persona__arrow" src="assets/arrow.svg" alt="">
            </div>
            <div class="persona__bio-wrap">
              <div class="persona__bio">
                <img class="persona__close" src="assets/close.svg" alt="">
                <div class="persona__content content">
                  <p>
                    Dimitri is Chairman of Titan Cement Group, a cement 
                    and building materials producer active since 1902. 
                    The group directly employs about 5,500 people, 
                    operates cement plants in 10 countries, and is 
                    active in many more.Prior to joining Titan in 1989, 
                    Dimirti started his career as a business consultant 
                    for McKinsey & Company in the USA and Germany.
                  </p>
                  <p>
                    He is Chairman of the Board of the Hellenic Federation 
                    of Enterprises (SEV), Vice-Chairman of the European 
                    Round Table for Industry (ERT) and chairs the ERT’s 
                    Energy Transition & Climate Change Committee. 
                    He is a member of the Board of the Foundation for 
                    Economic and Industrial Research (IOBE), the 
                    Hellenic Foundation for European and Foreign Policy 
                    (ELIAMEP), and of Endeavor Greece.
                  </p>
                  <p>
                    He holds a M.Sc. 
                    in Electrical Engineering from the Swiss Federal 
                    Institute of Technology (ETHZ) and an MBA 
                    from Harvard Business School.
                  </p>
                </div>
                <span class="persona__shadow"></span>
              </div>
            </div>
          </article>
          <article class="split__part persona">
            <div class="persona__card">
              <figure class="persona__image">
                <img src="assets/images/Mike Krzan.jpg" width="152" height="160" alt="Mike Krzan" />
              </figure>
              <h3 class="persona__title">Mike Krzan</h3>
              <div class="persona__desc">Advisor</div>
              <img class="persona__arrow" src="assets/arrow.svg" alt="">
            </div>
            <div class="persona__bio-wrap">
              <div class="persona__bio">
                <img class="persona__close" src="assets/close.svg" alt="">
                <div class="persona__content content">
                  <p>
                    Mike brings a lifetime of experience in building and 
                    running high-performing patient services organizations, 
                    having spent more than 20 years in the space. He led 
                    Biogen’s patient services center in North Carolina 
                    for more than a decade, and prior to that was a SVP 
                    for member services and pharmacy operations at Medco. 
                  </p>
                  <p>
                    While at Biogen, Mike was a member of the US Senior 
                    Leadership Team, developed and set the direction for 
                    the patient services organization to support $8B of 
                    revenue, launched seven products (including a blockbuster 
                    drug and an orphan drug), and collaborated with 
                    field sales leaders to identify trends, define 
                    tactics for improved performance, and ensure national 
                    team alignment. 
                  </p>
                  <p>
                    He holds a BS in Pharmacy 
                    from Duquesne University.
                  </p>
                </div>
                <span class="persona__shadow"></span>
                <a href="https://www.linkedin.com/in/mike-krzan" target="_blank" class="linkedin">
                  <svg id="Layer_1" data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 40">
                    <g id="Group_330" data-name="Group 330" fill="#fff">
                      <path id="Path_177" data-name="Path 177" class="cls-1" d="m13.27,31.23h-5.06V15.17h4.97v16.06h.09Zm-2.53-18.21c-1.6-.09-2.82-1.46-2.73-3.06.08-1.47,1.26-2.65,2.73-2.73,1.6.09,2.82,1.46,2.73,3.06-.08,1.47-1.26,2.65-2.73,2.73Zm21.25,18.21h-4.96v-7.83c0-1.87,0-4.3-2.62-4.3s-2.99,2.09-2.99,4.11v7.94h-5.05v-15.99h4.78v2.15h.1c.98-1.69,2.81-2.7,4.77-2.62,5.06,0,6,3.36,6,7.66v8.87h-.01Z"/>
                    </g>
                  </svg>
                </a>
              </div>
            </div>
          </article>

          <article class="split__part persona">
            <div class="persona__card">
              <figure class="persona__image">
                <img src="assets/images/Angelos.png" width="152" height="160" alt="Angelos Kapsimanis" />
              </figure>
              <h3 class="persona__title">Angelos Kapsimanis</h3>
              <div class="persona__desc">Chief Technology Officer</div>
              <img class="persona__arrow" src="assets/arrow.svg" alt="">
            </div>
            <div class="persona__bio-wrap">
              <div class="persona__bio">
                <img class="persona__close" src="assets/close.svg" alt="">
                <div class="persona__content content">
                  <p>
                    Angelos has been working in the tech industry for more than two decades, 
                    with experience across 65+ countries. He has led teams across multiple 
                    verticals and industries, with a focus on data, machine learning, and AI.
                  </p>
                  <p>
                    He has spent a significant amount of his career in the FinTech industry, 
                    helping Klarna to expand globally and reach a valuation of $70B. 
                    While at Klarna he managed teams interspersed across the planet, 
                    focusing on analytics, machine learning, real-time decision making, 
                    and risk management. Prior to Klarna, Angelos built the whole technology 
                    function for Motionlogic, an analytics company that is part of the Deutsche 
                    Telekom group, and helped it achieve a 52-fold increase in revenues in 3 years. 
                    He bootstrapped and successful led to exit Aton Solar, which developed embedded 
                    systems and telemetry solution for solar energy facilities.
                  </p>
                  <p>
                    He holds an MS in Machine Learning from Georgia Tech, a second Masters 
                    in Computational Statistics from De Montfort University in the UK, and a 
                    BS in Industrial Informatics in the University of Applied Sciences in Kavala, Greece.
                  </p>
                </div>
                <span class="persona__shadow"></span>
                <a href="https://www.linkedin.com/in/angeloskapsimanis/" target="_blank" class="linkedin">
                  <svg id="Layer_1" data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 40">
                    <g id="Group_330" data-name="Group 330" fill="#fff">
                      <path id="Path_177" data-name="Path 177" class="cls-1" d="m13.27,31.23h-5.06V15.17h4.97v16.06h.09Zm-2.53-18.21c-1.6-.09-2.82-1.46-2.73-3.06.08-1.47,1.26-2.65,2.73-2.73,1.6.09,2.82,1.46,2.73,3.06-.08,1.47-1.26,2.65-2.73,2.73Zm21.25,18.21h-4.96v-7.83c0-1.87,0-4.3-2.62-4.3s-2.99,2.09-2.99,4.11v7.94h-5.05v-15.99h4.78v2.15h.1c.98-1.69,2.81-2.7,4.77-2.62,5.06,0,6,3.36,6,7.66v8.87h-.01Z"/>
                    </g>
                  </svg>
                </a>
              </div>
            </div>
          </article>

          <article class="split__part persona">
            <div class="persona__card">
              <figure class="persona__image">
                <img src="assets/images/Oleg.png" width="152" height="160" alt="Oleg Nodelman" />
              </figure>
              <h3 class="persona__title">Oleg Nodelman</h3>
              <div class="persona__desc">Board member</div>
              <img class="persona__arrow" src="assets/arrow.svg" alt="">
            </div>
            <div class="persona__bio-wrap">
              <div class="persona__bio">
                <img class="persona__close" src="assets/close.svg" alt="">
                <div class="persona__content content">
                  <p>
                    Oleg is the founder and Portfolio Manager of EcoR1 Capital LLC, 
                    a biotech-focused investment fund established in 2013, 
                    which invests in companies at all stages of research and 
                    development. With nearly twenty years of experience in 
                    biotech investing, he has expertise in all aspects of 
                    investment management and deep roots in the biotech 
                    and scientific communities. 
                  </p>
                  <p>
                    Before founding EcoR1, Oleg was a portfolio manager at BVF 
                    Partners, one of the first hedge funds dedicated to the 
                    biotechnology sector. He currently serves as a Board 
                    Member for Prothena Biosciences (NASDAQ: PRTA), AnaptysBio 
                    (Nasdaq: ANAB), Nuvation Bio (Nasdaq: NUVB), Panacea 
                    (Nasdaq: PANA), Scorpion Therapeutics, Aktis Oncology, 
                    ReCode, and Paratus. 
                  </p>
                  <p>
                    Oleg holds a BS in Foreign Service with a concentration in 
                    Science and Technology from Georgetown University.
                  </p>
                </div>
                <span class="persona__shadow"></span>
                <a href="https://www.linkedin.com/in/oleg-nodelman-375131/" target="_blank" class="linkedin">
                  <svg id="Layer_1" data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 40">
                    <g id="Group_330" data-name="Group 330" fill="#fff">
                      <path id="Path_177" data-name="Path 177" class="cls-1" d="m13.27,31.23h-5.06V15.17h4.97v16.06h.09Zm-2.53-18.21c-1.6-.09-2.82-1.46-2.73-3.06.08-1.47,1.26-2.65,2.73-2.73,1.6.09,2.82,1.46,2.73,3.06-.08,1.47-1.26,2.65-2.73,2.73Zm21.25,18.21h-4.96v-7.83c0-1.87,0-4.3-2.62-4.3s-2.99,2.09-2.99,4.11v7.94h-5.05v-15.99h4.78v2.15h.1c.98-1.69,2.81-2.7,4.77-2.62,5.06,0,6,3.36,6,7.66v8.87h-.01Z"/>
                    </g>
                  </svg>
                </a>
              </div>
            </div>
          </article>

        </div>
      </div>
    </section>

  </main>

  <footer class="container container--footer">
    <a href="https://www.linkedin.com/company/epikast/" target="_blank" aria-label="Linkedin" class="linkedin">
      <svg id="Layer_1" data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 40">
        <g id="Group_330" data-name="Group 330" fill="#000033">
          <path id="Path_177" data-name="Path 177" class="cls-1" d="m13.27,31.23h-5.06V15.17h4.97v16.06h.09Zm-2.53-18.21c-1.6-.09-2.82-1.46-2.73-3.06.08-1.47,1.26-2.65,2.73-2.73,1.6.09,2.82,1.46,2.73,3.06-.08,1.47-1.26,2.65-2.73,2.73Zm21.25,18.21h-4.96v-7.83c0-1.87,0-4.3-2.62-4.3s-2.99,2.09-2.99,4.11v7.94h-5.05v-15.99h4.78v2.15h.1c.98-1.69,2.81-2.7,4.77-2.62,5.06,0,6,3.36,6,7.66v8.87h-.01Z"/>
        </g>
      </svg>
    </a>
    <div class="mail-copy">
      <span class="js-copy-year"></span> &copy; All rights reserved
    </div>
    <a href="index.html" class="logo"><img src="assets/logo.svg" alt="Epikast logo" width="128" height="27"/></a>
  </footer>
  
  <script src="js/swiper.min.js"></script>
  <script src="js/global.js"></script>
</body>
</html>